Special Issue

Application of Brachytherapy in Clinical Practice: 2nd Edition

Message from the Guest Editors

Interventional radiotherapy (brachytherapy) started after the discovery of radium by Maria Slodowoska Curie, and, at present, has clear indications for treatment in almost tumour sites. The present Special Issue is one of the few publications dedicated to interventional radiotherapy in Europe. The aim of this Special Issue is to present all the relevant clinical aspects of brachytherapy in all the tumour sites in a review or article format, considering future perspectives. To this end, clinical and medical brachytherapists work together with very specialised medical physicists, who are indispensable for the techniques' evolution. The submission of innovative clinical works in clinical practice and in physics. considering all the tumour sites is encouraged. Contributions exploring biological biomarkers and omics' brachytherapy, as well Montecarlo aspects in vivo dosimetry, among others, are welcome. We are soliciting reviews and original articles, and look forward to receiving your contributions.

Guest Editors

Dr. Elisa Placidi

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy

Dr. Àngeles Rovirosa

Fonaments Clinics Department, Faculty of Medicine, Universitat de Barcelon, Barcelona, Spain

Deadline for manuscript submissions

closed (20 January 2025)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/180617

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

